Pharmaceutical News

RSS

P5091 molecule triggers apoptosis in drug-resistant myeloma cells

A molecule that targets the cell's machinery for breaking down unneeded proteins can kill multiple myeloma cancer cells resistant to the frontline drug Velcade, researchers at Dana-Farber Cancer Institute have found.

11 Sep 2012

Combining two drugs may offer new and potent punch against cancer and other diseases

A new study by researchers at Weill Cornell Medical College shows combining two already-FDA approved drugs may offer a new and potent punch against diseases in which blood vessel growth is abnormal -- such as cancer, diabetic retinopathy, macular degeneration and rheumatoid arthritis.

11 Sep 2012

Oxyphenbutazone can kill drug resistant TB

An off-patent anti-inflammatory drug that costs around two cents for a daily dose in developing countries has been found by researchers at Weill Cornell Medical College to kill both replicating and non-replicating drug resistant tuberculosis in the laboratory -- a feat few currently approved TB drugs can do, and resistance to those is spreading.

11 Sep 2012

Increased use of powerful antipsychotic drugs to treat publicly insured children

A national study conducted by researchers at The Children's Hospital of Philadelphia (CHOP) shows increased use of powerful antipsychotic drugs to treat publicly insured children over the last decade. The study, published today in the journal Health Services Research, found a 62 percent increase in the number of Medicaid-enrolled children ages 3 to 18 taking antipsychotics, reaching a total of 354,000 children by 2007.

10 Sep 2012

Phase III data for Suvorexant, an investigational insomnia medicine, announced

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced new data for suvorexant, the investigational medicine Merck is developing for the treatment of insomnia. The new data are from one of the longest, continuously-dosed, placebo-controlled trials of a sleep medication ever conducted.

10 Sep 2012

Data from BioLineRx’s BL-7010 pre-clinical studies on celiac disease

BioLineRx, a biopharmaceutical development company, announced today that BL-7010, an orally available treatment for celiac disease, was found to be safe and well tolerated in pre-clinical studies conducted to date.

10 Sep 2012

Recent data from Silence Therapeutics’ Atu111 pre-clinical study on acute lung injury

Silence Therapeutics plc, a leading RNA interference (RNAi) therapeutics company is pleased to announce that recent data in pre-clinical models demonstrated the efficacy of Atu111 in acute lung injury.

10 Sep 2012

Link between recreational marijuana use and increased risk of testicular cancer

A new study from the University of Southern California (USC) has found a link between recreational marijuana use and an increased risk of developing subtypes of testicular cancer that tend to carry a somewhat worse prognosis.

10 Sep 2012

UK public oppose cancer drugs fund but support new pricing system for branded medicines

The public oppose the cancer drugs fund but support the new pricing system for branded medicines, according to a new study.

10 Sep 2012

FDA warns dietary supplement firms in Colorado and Texas

The U.S. Food and Drug Administration today issued warning letters to PruTect Rx, of Highlands Ranch, Colo., and Trinity Sports Group Inc., of Plano, Texas, for promoting products labeled as dietary supplements with claims to treat concussions and prevent or treat post-concussion syndrome and other neurological disorders.

7 Sep 2012

Genetic test to help prescribe proper dose of blood-thinner warfarin

Patients suffering from dangerous blood clots will receive genetic testing to help health professionals at the University of Illinois Hospital & Health Sciences System prescribe the proper dose of the blood-thinner warfarin.

7 Sep 2012

Pfizer announces settlement of Detrol LA patent litigation with Mylan

Pfizer Inc. announced that it has settled its litigation against Mylan Inc. and Mylan Pharmaceuticals Inc. relating to Pfizer's patents covering Detrol LA (tolterodine tartrate) extended-release capsules.

7 Sep 2012

American troops with noise-induced hearing loss, tinnitus may benefit from novel strategies

Antioxidants, dietary supplements and high-tech brain imaging are among some of the novel strategies that may help detect, treat and even prevent noise-induced hearing loss and tinnitus among American troops, according to researchers at Henry Ford Hospital.

7 Sep 2012

Pfizer, Mylan enter settlement agreement to resolve generic Detrol LA litigation

Mylan Inc. today announced that it and its subsidiary, Mylan Pharmaceuticals Inc., have entered into a settlement agreement with Pfizer Inc., Pharmacia & Upjohn Company LLC and Pfizer Health AB that will resolve the parties' patent litigation in connection with Mylan Pharmaceuticals' Abbreviated New Drug Application (ANDA) for Tolterodine Tartrate ER capsules, 2 mg and 4 mg, which is the generic version of Pfizer's Detrol LA, indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.

7 Sep 2012

BCAA supplementation may treat autism and/or epilepsy

An international team of researchers, led by scientists at the University of California, San Diego and Yale University schools of medicine, have identified a form of autism with epilepsy that may potentially be treatable with a common nutritional supplement.

7 Sep 2012

Mammalian target of rapamycin inhibitors can prevent radiation-induced tissue damage

Radiation therapy is one of the most widely used cancer treatments, but it often damages normal tissue and can lead to debilitating conditions. A class of drugs known as mammalian target of rapamycin (mTOR) inhibitors can prevent radiation-induced tissue damage in mice by protecting normal stem cells that are crucial for tissue repair, according to a preclinical study published by Cell Press in the September issue of the journal Cell Stem Cell.

7 Sep 2012

History of TB policy shows need for care, investment equity in developed, developing countries

In a 200th anniversary article for the New England Journal of Medicine, Salmaan Keshavjee of the Department of Global Health and Social Medicine at Harvard Medical School and Paul Farmer of Partners in Health "seek to elucidate the reasons for the anemic response to drug-resistant tuberculosis [TB] by examining the recent history of tuberculosis policy," they write.

7 Sep 2012

OncoMed announces data from demcizumab preclinical study on pancreatic cancer

OncoMed Pharmaceuticals, Inc., a clinical-stage company developing novel therapeutics that target cancer, today announced the online publication in Clinical Cancer Research of preclinical data demonstrating the potent anti-cancer activity of anti-DLL4 (demcizumab) in patient-derived pancreatic tumor models.

7 Sep 2012

Hebrew University researcher develops anti-inflammatory and anti-allergic family of drugs

A synthetic, anti-inflammatory and anti-allergic family of drugs to combat a variety of illnesses while avoiding detrimental side effects has been developed by a Hebrew University of Jerusalem researcher.

7 Sep 2012

Doctor and pharmacy shoppers at increased risk for drug-related death

A published study conducted by researchers at West Virginia University has found that doctor and pharmacy shoppers are at a greater risk for drug-related death.

7 Sep 2012

Pharmaceutical News

P5091 molecule triggers apoptosis in drug-resistant myeloma cells

Combining two drugs may offer new and potent punch against cancer and other diseases

Oxyphenbutazone can kill drug resistant TB

Increased use of powerful antipsychotic drugs to treat publicly insured children

Phase III data for Suvorexant, an investigational insomnia medicine, announced

Data from BioLineRx’s BL-7010 pre-clinical studies on celiac disease

Recent data from Silence Therapeutics’ Atu111 pre-clinical study on acute lung injury

Link between recreational marijuana use and increased risk of testicular cancer

UK public oppose cancer drugs fund but support new pricing system for branded medicines

FDA warns dietary supplement firms in Colorado and Texas

Genetic test to help prescribe proper dose of blood-thinner warfarin

Pfizer announces settlement of Detrol LA patent litigation with Mylan

American troops with noise-induced hearing loss, tinnitus may benefit from novel strategies

Pfizer, Mylan enter settlement agreement to resolve generic Detrol LA litigation

BCAA supplementation may treat autism and/or epilepsy

Mammalian target of rapamycin inhibitors can prevent radiation-induced tissue damage

History of TB policy shows need for care, investment equity in developed, developing countries

OncoMed announces data from demcizumab preclinical study on pancreatic cancer

Hebrew University researcher develops anti-inflammatory and anti-allergic family of drugs

Doctor and pharmacy shoppers at increased risk for drug-related death

Exploring the nanoscale: How AFM is transforming cosmetic science

Innovating Texture and Culture in Plant-Based Foods

Advancing brain microphysiological systems (bMPS)

Latest News